reports
- GlobalData Healthcare Department
CoLucid Pharmaceuticals Inc (CLCD) - Pharmaceuticals & Healthcare - De...
Summary CoLucid Pharmaceuticals Inc (CoLucid) is a pharmaceutical company that conducts research and develops new therapies. CoLucid’s lead product candidate Lasmiditan (COL-144), is an oral tablet that penetrates the central nervous system and selectively targets 5-HT1F receptors expressed in the trigeminal nerve pathway. It’s been designed to deliver efficacy for the acute treatment of migraine in adults without the vasoconstrictor activity and clinical limitations associated with previou...
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Conce...
NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD) stock prior to January 18, 2017. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of CoLucid Pharmaceuticals, Inc. to Eli Lilly & Co. (NYSE: LLY). Under the terms of the transaction (valued at approximately $960 Million) CoLucid Pharmaceuticals, Inc. shareholders will receive $...
Bragar Eagel & Squire, P.C. Is Investigating the Board of Directors of...
NEW YORK--(BUSINESS WIRE)-- Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of CoLucid Pharmaceuticals (NASDAQ:CLCD) stockholders concerning the proposed acquisition of the company by Eli Lilly and Company. CoLucid Pharmaceuticals is a Phase 3 clinical-stage biopharmaceutical company that is developing an oral 5-HT1F agonist (lasmiditan) for the acute treatment of migraine. The investigation concerns whether CoLucid’s board of directors failed to adequately shop the Company and obtain the best...
INVESTOR ALERT: Brower Piven Commences An Investigation Into The Propo...
STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of CoLucid Pharmaceuticals, Inc. (Nasdaq: CLCD) (“CoLucid” or the “Company”) relating to the proposed buyout of CoLucid by Eli Lilly and Company. Under the terms of the agreement, CoLucid shareholders are anticipated to receive $46.50 in cash for each share of CoLucid common stock hel...
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Conce...
NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD) stock prior to January 18, 2017. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of CoLucid Pharmaceuticals, Inc. to Eli Lilly & Co. (NYSE: LLY). Under the terms of the transaction (valued at approximately $960 Million) CoLucid Pharmaceuticals, Inc. shareholders will receive $...
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Pr...
STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of CoLucid Pharmaceuticals, Inc. (Nasdaq: CLCD) (“CoLucid” or the “Company”) relating to the proposed buyout of CoLucid by Eli Lilly and Company. Under the terms of the agreement, CoLucid shareholders are anticipated to receive $46.50 in cash for each share of CoLucid common stock hel...
Robbins Arroyo LLP: Acquisition of CoLucid Pharmaceuticals, Inc. (CLCD...
SAN DIEGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed acquisition of CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD) by Eli Lilly and Company (NYSE: LLY). On January 18, 2017, the two companies announced the signing of a definitive merger agreement pursuant to which Eli Lilly will acquire CoLucid. Under the terms of the agreement, CoLucid shareholders will receive $46.50 for each share of CoLucid common stock. View this information on the law firm's Shar...
COLUCID PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former SEC Attorney W...
DALLAS--(BUSINESS WIRE)-- Former United States Securities and Exchange Commission attorney Willie Briscoe is investigating potential claims against the Board of Directors of CoLucid Pharmaceuticals, Inc. (“CoLucid”) (NasdaqGM: CLCD) concerning the acquisition by Eli Lilly and Company. Under the terms of the agreement, valued at approximately $960 million, CoLucid shareholders will only receive $46.50 per CoLucid share owned. The consideration is significantly lower than at least one analyst’s estimated value of $58.00 per share. ...
COLUCID PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A...
WILMINGTON, Del.--(BUSINESS WIRE)-- Rigrodsky & Long, P.A.: Do you own shares of CoLucid Pharmaceuticals, Inc. (NASDAQ GM: CLCD)? Did you purchase any of your shares prior to January 18, 2017? Do you think the proposed buyout price is too low? Do you want to discuss your rights? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of CoLucid Pharmaceuticals, Inc. (“CoLucid” or the “Company”) ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.